The Technical Analyst
Sio Gene Therapies Inc. [SIOX]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Sio Gene Therapies Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
22.63% $0.478
America/New_York / 7 feb 2024 @ 15:58
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 35.36 mill |
| EPS: | -0.390 |
| P/E: | -1.226 |
| Earnings Date: | Feb 12, 2024 |
| SharesOutstanding: | 73.98 mill |
| Avg Daily Volume: | 0.0624 mill |
| RATING 2024-02-07 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Sell | |
| Return On Asset: | Neutral | |
| DE: | Sell | |
| P/E: | Sell | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/21 | 4/21 | 1/22 | 2/22 | 3/22 | 4/22 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -1.226 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.21x |
| Company: PE -1.226 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.456 - 0.500 ( +/- 4.60%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2022-02-08 | Meswani Parag V | Buy | 153 700 | Restricted Stock Units |
| 2022-02-08 | Nassif David W. | Buy | 546 500 | Restricted Stock Units |
| 2022-01-28 | Meswani Parag V | Sell | 0 | Common Stock |
| 2022-01-28 | Meswani Parag V | Sell | 15 625 | Stock Option (Right to Buy) |
| 2022-01-28 | Meswani Parag V | Sell | 12 500 | Stock Option (Right to Buy) |
| INSIDER POWER |
|---|
| 0.00 |
| Last 89 transactions |
| Buy: 137 127 498 | Sell: 478 048 |
Forecast:
01:40 - $0.399
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.478 (22.63% ) |
| Volume | 0.0076 mill |
| Avg. Vol. | 0.0624 mill |
| % of Avg. Vol | 12.16 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For SIOX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
SIOX
Sio Gene Therapies Inc., a clinical-stage company, focuses on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases. It has a license agreement with Oxford BioMedica (UK) Ltd. to develop and commercialize AXO-Lenti-PD and related gene therapy products; and The University of Massachusetts Medical School to develop and commercialize gene therapy product candidates, including AXO-AAV-GM1 and AXO-AAV-GM. The company was formerly known as Axovant Gene Therapies Ltd. and changed its name to Sio Gene Therapies, Inc. in November 2020. Sio Gene Therapies, Inc. was incorporated in 2014 and is based in New York, New York.
Latest Press Releases
2024-02-02 07:00:00 - Press Release
Sio Gene Therapies, Inc. To File For Dissolution And Declare An Initial Liquidating Distribution Of $0.435 Per Share
Parsippany, n.j., feb. 02, 2024 (globe newswire) -- sio gene therapies, inc. ("sio") today announced that it expects to file a certificate of dissolution (the "certificate of dissolution") with the secretary of state of the state of delaware, as contemplated by the plan of complete liquidation and dissolution (the "plan") previously approved by sio's board of directors and stockholders, on february 7, 2024. the certificate of dissolution, which is expected to become effective at 4:00 p.m. eastern time on february 7, 2024 (the "effective time"), provides for the dissolution of sio under the general corporation law of the state of delaware (the "dgcl").
2022-02-02 07:00:00 - Press Release
Sio Gene Therapies To Present At The 18th Annual Worldsymposium™ 2022
New york and durham, n.c., feb. 02, 2022 (globe newswire) -- sio gene therapies inc. (nasdaq: siox), a clinical-stage company focused on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases, today announced that it will present data in an oral platform presentation and two poster presentations at the 18th annual worldsymposium™ 2022, to be held february 7-11, 2022.
2021-10-04 09:04:00 - Press Release
Update: Sio Gene Therapies To Present New Data At The European Society Of Gene And Cell Therapy Virtual Congress 2021
Oral presentation to discuss new data updates from the high- and low-dose cohorts from the ongoing phase 1/2 trial of axo-aav-gm1 for the treatment of gm1 gangliosidosis oral presentation to discuss new data updates from the high- and low-dose cohorts from the ongoing phase 1/2 trial of axo-aav-gm1 for the treatment of gm1 gangliosidosis
2021-10-04 07:30:00 - Press Release
Sio Gene Therapies To Present New Data At The European Society Of Gene And Cell Therapy Virtual Congress 2021
Oral presentation to discuss new data updates from the high- and low-dose cohorts from the ongoing phase 1/2 trial of axo-aav-gm1 for the treatment of gm1 gangliosidosis oral presentation to discuss new data updates from the high- and low-dose cohorts from the ongoing phase 1/2 trial of axo-aav-gm1 for the treatment of gm1 gangliosidosis
2021-09-23 07:30:00 - Press Release
Sio Gene Therapies To Participate In Upcoming Conferences
New york and research triangle park, n.c., sept. 23, 2021 (globe newswire) -- sio gene therapies inc. (nasdaq: siox), a clinical-stage company focused on developing gene therapies to radically improve the lives of patients with neurodegenerative diseases, announced today that the company will participate in select upcoming investor and scientific conferences. details can be found below.
Latest News
2022-12-14 11:51:20 - PennyStocks
Penny Stocks To Buy Now? 10 Stocks Under $1 To Watch
2022-10-14 12:53:33 - PennyStocks
3 Hot Penny Stocks To Buy For Under $1 Right Now
If you're watching the action in the stock market today, you're seeing plenty of chop. The U.S. dollar's strength has pushed broader markets lower, but a mix of positive and negative economic against this week's PPI data and CPI data has brought much more push-pull action.
2022-04-28 09:06:08 - Benzinga
Sio Gene Therapies Ditches Two Remaining Programs, Seeks Buyer(s), Shares Plunge
Sio Gene Therapies Inc (NASDAQ: SIOX) will terminate its licensing agreement with the University of Massachusetts to develop and commercialize gene therapy product candidates, including AXO-AAV-GM1 and AXO-AAV-GM2, for GM1 gangliosidosis and GM2 gangliosidosis, respectively. In.
2022-02-02 07:00:00 - GlobeNewsWire
Sio Gene Therapies to Present at the 18th Annual WORLDSymposium™ 2022
NEW YORK and DURHAM, N.C., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases, today announced that it will present data in an oral platform presentation and two poster presentations at the 18th Annual WORLDSymposium™ 2022, to be held February 7-11, 2022.
2022-02-01 05:51:58 - Benzinga
Sio Gene Terminates Parkinson's Gene Therapy Pact With Oxford Biomedica, Announces CEO Transition
Sio Gene Therapies Inc SIOX has decided to terminate its licensing agreement with Oxford Biomedica for AXO-Lenti-PD, its lentiviral gene therapy program for Parkinson's disease. [LIVE NOW ON YOUTUBE] Click Here to Watch a FREE MASTERCLASS on the Ultimate Bear Market Survival Guide with Matt Maley!
2021-12-27 14:06:20 - Seeking Alpha
My Favorite Stock For 2022: Sio Gene Therapies
2021-10-26 14:55:17 - Seeking Alpha
Sio Gene Therapies: Risk-On Gene Therapy Prospect May Offer Value For Money
Sio used to be called Axovant - an unsuccessful biotech that attempted to bring several therapies to market, including an Alzheimer's treatment.
2021-10-25 19:56:32 - Seeking Alpha
Sio Gene Therapies: Excellent Data And News Obscured By Officer's Departure
SIOX presented excellent data in its higher dose GM1 Gangliosidosis gene therapy program. Unfortunately, after hours that same day, its chief research and development officer announced he was moving on to another company.
2021-10-21 15:45:56 - PennyStocks
Top Penny Stocks to Buy Now? 3 Under $4 to Watch
These under $4 penny stocks could be worth taking a look at The post Top Penny Stocks to Buy Now? 3 Under $4 to Watch appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2021-10-21 07:34:16 - Pulse2
SIOX Stock: Why It Increased Today
The stock price of Sio Gene Therapies Inc (NASDAQ: SIOX) increased by over 14% pre-market today. This is why it happened.